1 / 14

Haemostatics

Haemostatics. Virchow’s Triad. Hypercoagulable state. Stasis/turbulence. Endothelial injury. Clotting Processes. 1) Vascular Phase (immediate): Transient vasoconstriction Exposure of underlying subendothelium Local factors. Clotting Processes (cont.). 2) Platelet Phase (15 sec):

ogden
Download Presentation

Haemostatics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Haemostatics

  2. Virchow’s Triad Hypercoagulable state Stasis/turbulence Endothelial injury

  3. Clotting Processes 1) Vascular Phase (immediate): • Transient vasoconstriction • Exposure of underlying subendothelium • Local factors

  4. Clotting Processes (cont.) 2) Platelet Phase (15 sec): • Adhesion to subendothelium (mediated by von Willebrand factor) • Secretion of chemicals (5-TAPP) • 5HT: promotes vasoconstriction • Thromboxane A2: ↑ platelet aggregation • Adenosine diphosphate: activates GpIIb/IIIa to ↑ platelet binding • PAF (platelet activating factor): ↑ platelet aggregation • Plasminogen: localises clot formation at injury site *Aspirin, Dipyridamole *Clopidogrel, dipyridamole *Fibrinolytics (streptokinase, urokinase)

  5. Clotting Processes (cont.) 3) Coagulation Phase: Extrinsic Pathway: Exposure to Tissue Factor Intrinsic Pathway: Exposure to collagen/glass XIIa XII VII VIIa + TF XI XIa IX IXa X Xa VIII VIIIa XIII XIIIa II IIa (thrombin) V Va I Ia (fibrin) • Warfarin blocks II, VII, IX, X (TV Channels) • Heparins activate III  blocks Iia and Xa (low molecular weight heparins especially blocks Xa) • Dabigatran blocks II (thrombin). Is currently trialed as a less fussy (wrt interactions and monitoring) alternative to warfarin

  6. Clotting Processes (cont.) • Coagulation Limiters: restricted to sites of exposed phospholipids • Antithrombin III: blocks IIa, Ixa, Xa, XIa and XIIa • Protein C: inactivates V, VIII • Protein S is a cofactor for Protein C • Protein C is activated by thrombin (IIa) • Tissue Factor Pathway Inhibitor (TFPI): blocks Xa, IIa

  7. Bleeding Tests

  8. Antiplatelet Medications

  9. Fibrinolytics

  10. Anticoagulants

  11. Haemostasis in Bruises • Types of bruises: • Damaged vessels (e.g. trauma, vasculitis) • Changes in blood (e.g. thrombocytopaenia) • Changes in dermis (e.g. senile purpura, scurvy) • Bruise = blood vessel damage that causes leaking into surrounding connective tissue • Petechiae are a type of bruising (a tiny red-purple spot; purpura and ecchymosesare similar but are larger) • Not to be confused with telangiectasia(capillary dilatation, e.g. from old age, steroid use, irradiation, liver failure)

  12. Purpura – large red-purple spots (>10mm) Petechiae – tiny red-purple spots (<3mm) Telangiectasia – dilated capillary network Purpura – bigger red-purple spots (3-10mm)

  13. Relevance to Dengue Fever • The patient had petechiae • The petechiae are possibly a result of thrombocytopaenia or platelet dysfunction  makes it easier to break capillaries • Capillary vasodilationin critical phase could potentially worsen symptoms by increasing bleeding

  14. References • Sherwood. Human Physiology 6th edition • Rang and Dale’s Pharmacology • Cross and Underwood. General Systemic Pathology • Kuma. Robbins and Cotran Pathologic Basis of Disease, Professional Edition , 8th ed • AMH • Therapeutic Guidelines • Australian Prescriber: http://www.australianprescriber.com/magazine/32/2/51/5

More Related